Tyra Biosciences (TYRA) Stock Forecast & Price Target

Tyra Biosciences is supported by a differentiated precision-medicine platform and a pipeline aimed at FGFR3, FGFR4/3, and FGFR1/2/3, which together seek to address toxicity and resistance shortcomings of first-generation pan-FGFR inhibitors. Its oral FGFR programs still show encouraging fundamental validation, including 0/22 Grade 3 treatment-related adverse events at 60mg and no clinically significant hyperphosphatemia, nail, or ocular toxicity, while the ACH program has already shown cross-molecule support with +2.4cm/year annualized height velocity in a small low-dose dataset. Even though the urothelial readthrough looks narrower after SURF302 underperformed, the company retains multiple catalysts, including initial six-month BEACH301 data from ~25 children across five dose levels at end-1Q27 and SURF303 data expected in 2027.

Tyra Biosciences is a clinical-stage biotechnology company whose prospects appear highly dependent on narrow, unproven clinical readouts, including whether BEACH301 can clear >6cm/year AHV without chronic pediatric safety issues and whether dabogratinib can sustain a practical ~70% CR bar in urothelial carcinoma. The company has only five BEACH301 sentinel dose levels cleared from 0.125-0.625mg/kg, with ~25 children ages 5-10 and initial 6-month AHV and safety not expected until end-1Q27, while the current 60mg dataset still leaves just one PR on treatment and requires additional CR maturation or stronger 70mg exposure-response to restore confidence. Financially, the valuation framework is already highly contingent, applying an 11% discount rate, 2% terminal growth, and low approval probabilities of 20%, 40%, 40%, and 35%, with risk of dilution and a long registrational path reinforcing a negative outlook.